CTLA-4 blockade increases antigen-specific CD8(+) T cells in prevaccinated patients with melanoma: three cases
about
Association of genetic polymorphisms with osteosarcoma risk: a meta-analysisMonitoring of regulatory T cell frequencies and expression of CTLA-4 on T cells, before and after DC vaccination, can predict survival in GBM patientsImmunologic responses to xenogeneic tyrosinase DNA vaccine administered by electroporation in patients with malignant melanomaDevelopment of thyroglobulin antibodies after GVAX immunotherapy is associated with prolonged survivalTissue biomarkers in melanoma patients treated with TILDifferential CTLA-4 expression in human CD4+ versus CD8+ T cells is associated with increased NFAT1 and inhibition of CD4+ proliferation.Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumabFuture perspectives of prostate cancer therapy.Immunotherapies: the blockade of inhibitory signals.Comparison of glioma-associated antigen peptide-loaded versus autologous tumor lysate-loaded dendritic cell vaccination in malignant glioma patients.The interaction between murine melanoma and the immune system reveals that prolonged responses predispose for autoimmunity.Immunological markers and clinical outcome of advanced melanoma patients receiving ipilimumab plus fotemustine in the NIBIT-M1 study.Antitumor granuloma formation by CD4+ T cells in a patient with rapidly progressive melanoma experiencing spiking fevers, neuropathy, and other immune-related toxicity after treatment with ipilimumab.Randomized phase I pharmacokinetic study of ipilimumab with or without one of two different chemotherapy regimens in patients with untreated advanced melanoma.Blockade of cytotoxic T-lymphocyte antigen-4 as a new therapeutic approach for advanced melanoma.Immunoediting and antigen loss: overcoming the achilles heel of immunotherapy with antigen non-specific therapiesIpilimumab administered to metastatic melanoma patients who progressed after dendritic cell vaccination.Checkpoint modulation in melanoma: an update on ipilimumab and future directions.Identification of Novel HLA-A*0201-Restricted CTL Epitopes in Chinese Vitiligo Patients.Combined VEGFR and CTLA-4 blockade increases the antigen-presenting function of intratumoral DCs and reduces the suppressive capacity of intratumoral MDSCs.Metastatic melanoma: the new era of targeted therapy.Next-generation peptide vaccines for advanced cancer.Preclinical vaccines against mammary carcinoma.Therapeutic vaccines for cancer: an overview of clinical trials.Ipilimumab induces simultaneous regression of melanocytic naevi and melanoma metastases.Engineering of a self-adjuvanted iTEP-delivered CTL vaccine.Increased infiltration and tolerised antigen-specific CD8+ TEM cells in tumor but not peripheral blood have no impact on survival of HCMV+ glioblastoma patients.Exomics and immunogenics: Bridging mutational load and immune checkpoints efficacy.Exacerbation of Autoimmune Thyroiditis by CTLA-4 Blockade: A Role for IFNγ-Induced Indoleamine 2, 3-Dioxygenase.Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab.Clinical and immunologic evaluation of three metastatic melanoma patients treated with autologous melanoma-reactive TCR-transduced T cells.Significant association between cytotoxic T lymphocyte antigen 4 +49G>A polymorphism and risk of malignant bone tumors.Current challenges for cancer vaccine adjuvant development.Innate immune cells for immunotherapy of autoimmune and cancer disorders.Synergistic effects of host B7-H4 deficiency and gemcitabine treatment on tumor regression and anti-tumor T cell immunity in a mouse model.Combined treatment with ipilimumab and intratumoral interleukin-2 in pretreated patients with stage IV melanoma-safety and efficacy in a phase II study.Novel and enhanced anti-melanoma DNA vaccine targeting the tyrosinase protein inhibits myeloid-derived suppressor cells and tumor growth in a syngeneic prophylactic and therapeutic murine model.Features of Effective T Cell-Inducing Vaccines against Chronic Viral Infections.NY-ESO-1 Based Immunotherapy of Cancer: Current Perspectives.CTLA-4 (CD152) enhances the Tc17 differentiation program
P2860
Q26797065-C3D8DD97-9110-42EA-991B-9BDE205DC9C9Q28730798-B27F8B5B-85A1-46A1-AF28-40AEE0367A3CQ33606137-6A437BD2-108A-4248-B32C-B408E29DD060Q34353251-11AC99E3-6088-4378-A932-0DF00430C960Q34531444-A9B9AE8F-352D-496C-A852-66E62D5BF26FQ34824109-7DF188B5-909E-42AA-AAE8-F637D9A91EEFQ35289145-1754EEB3-3FCE-4ECF-B163-C06B8BC64784Q36076453-F9781FB8-2363-45F8-AC0E-E1E8EA50A031Q36431677-93E7EF83-3A7C-49B9-B784-7331DD20F720Q36597942-F5DB25B5-FFFA-478B-AD1B-5D5044424691Q36694921-6DDD5733-F18C-454B-84B2-CB305F86C6DEQ36711007-09944BFD-28A9-4D67-996D-1F92F618478BQ36938806-82D1B243-40A9-4FE0-BE76-2C7F8EF0E800Q36980597-4F097E75-1169-4639-8B21-4A865F9D7FF4Q37014061-4810531D-2247-4971-A133-C90E934D1D8CQ37047061-C0E4182C-46B4-46D3-91D3-5E0BE3D7E472Q37224609-553A6782-0F6B-4022-ABCE-853A75348820Q37237761-AE0A5F92-E0CA-4DDD-B658-C1711D86499AQ37399612-21C9B330-E5DC-4F49-99A5-CEFDEAE77C50Q37447879-C771E04B-0906-4EDF-B434-577F9FC9ADEFQ37996425-5CB04FB6-2F54-475D-A58D-B1B2BBF25F72Q38056246-D78EF81F-88AF-43B5-91E9-BF7BD4CCF10CQ38160252-F2EFB5BA-CB7D-43B1-8C0F-003D5DD0127FQ38227030-D82C7E31-FC4F-45E6-AA24-7E71729A3EACQ40065644-DE0B4B6C-625B-43B1-B18D-5A647931C175Q40248942-0E2FBE2D-202C-4042-A70A-40167C2635DCQ41338250-F6067E20-9EC9-4A09-B8CB-5CE91F1EA03CQ41983246-D9A26787-9BAF-4799-8A58-8336DFA9855FQ42375749-C4A77517-562E-40AA-A56C-D7B8E3793EF1Q44017442-BA659396-B6BB-4F11-83B7-212452F40557Q47625086-25E7889E-1E9F-4ECA-BE50-B82CBC942256Q47896312-B735D55D-29F7-4C3B-AFA8-9E6B739CCA76Q48160317-1F32BC78-C09C-4EC8-AE7E-E992C263AF26Q48316500-F1C03964-579B-4365-9521-A10FBB8755B9Q48365640-EA445FA3-A092-4AE4-8F22-B45467AC4C1AQ48891121-60A86025-A3CB-4912-9FDD-5D648F5E2C49Q50220559-775134EB-EB05-4C1B-9EEF-FF54DAEDD0BBQ50335281-19543B90-9919-4610-ACDB-C90D0FEEC0D0Q54945263-1A80D011-4F6F-4E66-9D0A-8DD11DAD752AQ56896815-D449F668-F904-487F-831E-8110004DB9E5
P2860
CTLA-4 blockade increases antigen-specific CD8(+) T cells in prevaccinated patients with melanoma: three cases
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
CTLA-4 blockade increases anti ...... nts with melanoma: three cases
@en
type
label
CTLA-4 blockade increases anti ...... nts with melanoma: three cases
@en
prefLabel
CTLA-4 blockade increases anti ...... nts with melanoma: three cases
@en
P2093
P2860
P50
P1476
CTLA-4 blockade increases anti ...... nts with melanoma: three cases
@en
P2093
Achim Jungbluth
Brian Ginsberg
David Page
Humilidad F Gallardo
Jedd D Wolchok
Jianda Yuan
Klaus Busam
Lloyd J Old
Nina Bhardwaj
Teresa Rasalan
P2860
P2888
P304
P356
10.1007/S00262-011-1011-9
P577
2011-04-05T00:00:00Z